Avenciguat
Sponsors
Boehringer Ingelheim
Conditions
Chronic Kidney DiseaseHypertension, PortalLiver CirrhosisLiver Diseases
Phase 2
A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney Disease
CompletedNCT04736628
Start: 2021-04-27End: 2023-09-21Updated: 2024-09-04
A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)
TerminatedNCT05282121
Start: 2022-06-28End: 2024-06-07Updated: 2025-09-04
A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly
TerminatedNCT06082843
Start: 2024-01-03End: 2024-05-30Updated: 2025-06-12